Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q2 Half Year Report 2021

August 5, 2021

Q1 Report 2021

May 6, 2021

Investor presentations

HCW Presentation September 13, 2021

Corporate Deck August 2021

Canaccord Presentation August 12, 2021

Wedbush Presentation August 11, 2021

Corporate Deck July 2021

Corporate Deck June 2021

Corporate Deck May 2021 v2

Corporate Deck May 2021

1 2 3 5

Press Releases

ObsEva SA Announces Appointments to its Board of Directors and Scientific Advisory Board

press release

January 17, 2014

Geneva, Switzerland, 17 January 2014 – ObsEva, a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for…

Read more

ObsEva SA announces CHF 32 Million Series A funding from leading Venture Capital firms and a license agreement with MerckSerono

press release

August 29, 2013

Geneva, Switzerland, 29 August 2013 – ObsEva today announced the closing of a CHF 32 million Series-A financing round (€25.6 million)….

Read more

Other ObsEva press releases

press release

January 1, 2000

Read more
1 63 64 65

General Meetings

ObsEva Annual General Meeting 2019

May 8, 2019

Read more

ObsEva Annual General Meeting 2018

May 9, 2018

Read more
1 2 3

Upcoming Events

Sorry, there are no events available yes.

 

Contacts

ObsEva Switzerland Office

Chemin des Aulx,12

1228, Plan-Les-Ouates, Geneva, Switzerland

+41 (0)22 552 3840


contact@obseva.ch

Media

Shauna Dillon

+41 (0)22 552 1550 Office

+41 79 360 3533 Mobile

shauna.dillon@obseva.ch

Investor relations


.


Joyce Allaire

+1 (617)-435-6602

ir@obseva.ch

Clinical studies




clinicaltrials@obseva.ch

HR Office

Charlotte Cadoux


charlotte.cadoux@obseva.ch

CEO Office

+41 (0)22 552 1550


shauna.dillon@obseva.ch

 

Sign up for news

 
 

    * Type:


    InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












    Read our privacy policy here.


     

    Are you sure you want to leave ObsEva.com?

    We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

    Continue to link

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue